ABC Heart Fail Cardiomyop 2024; 4(1): e20240018
Neprilysin Inhibitors: History, Pharmacology, Pharmacological-Clinical Evidence, and Clinical Practice, from the Risk of Angioedema to a Pillar of Therapy in Heart Failure
Paulo Vinicius Ramos Souza
, Vagner Madrini Junior
, Fabio Fernandes
, Fábio Danziato Fernandes, Felix José Alvarez Ramires
Abstract
The recognition that alterations in the regulation of the neurohormonal axis are the main factor behind the development and progression of heart failure was fundamental to constructing the pillars of therapy currently available for the treatment of this syndrome.
The main objective of this review is to understand the entire historical and pharmacological process that has led neprilysin inhibition to become one of the pillars of heart failure treatment.
For years, there was a gap in drug therapy for heart failure with reduced ejection fraction, and it took years to understand neprilysin inhibition, establish its safety, and confirm its effects, in order to achieve the beneficial results we have today.
Keywords: Heart Failure; Neprilysin
962
